PH10.16 | PH10.16 | Cautious Prescribing for Dependence-Producing Drugs — SDL Guide — Summary & Reflection

KEY TAKEAWAYS

Dependence-producing drugs include opioids (Schedule X NDPS — mu-receptor agonists) and benzodiazepines (Schedule X — GABA-A modulators), as well as Z-drugs, tramadol (Schedule H1), and alcohol/tobacco. Tolerance (reduced drug effect), physical dependence (withdrawal on cessation), and addiction (compulsive use despite harm) are distinct phenomena requiring different clinical responses. The cautious prescribing framework for dependence-producing drugs has five steps: indication screening, dose minimisation, duration limitation, monitoring for aberrant behaviour, and tapering strategy. Benzodiazepine withdrawal from long-term use can cause life-threatening seizures — always taper, never stop abruptly. Opioids in cancer pain do not have an arbitrary dose ceiling — the right dose is the one that controls pain safely. For established dependence, refer to psychiatry/de-addiction services; in the interim, apply harm reduction principles. Naloxone availability and safe storage education are appropriate for patients on long-term opioids.

REFLECT

Consider the prescriber's role in India's prescription drug misuse problem. Benzodiazepines are widely available in Indian pharmacies — sometimes without a prescription despite Schedule X requirements. If a patient presents to you already dependent on a benzodiazepine obtained from an informal source, your options are constrained: you cannot simply refuse (withdrawal risk) and you may not be able to prescribe for dependence maintenance without a clear therapeutic indication. How does this clinical-regulatory tension shape your approach? Consider also: the WHO pain ladder for cancer pain mandates that opioids be available for severe pain — yet in many Indian states, access to oral morphine for palliative care remains severely restricted due to regulatory barriers. How do you navigate the tension between regulating drugs to prevent misuse and ensuring access for legitimate therapeutic use?